If the stock market had a mood ring right now, it’d be flashing red and screaming for a therapist. Big tech is flailing (Nvidia and Google are down almost 20%), retail investors are hiding in cash like it’s their childhood blankie (gold is back), and the S&P 500 has the swagger of someone who just lost a fight with a vending machine. 

But with all of that said, one company grabbed my attention after seeing their 280% stock surge so far this year. Say hello to Nutex Health… the company you didn’t know you needed on your watchlist… until now.

So, what does Nutex even do? Well, they’re in healthcare… specifically, they run a lean, mean network of micro-hospitals that deliver high-margin emergency and outpatient care. Picture smaller, smarter hospitals that don’t feel like they were designed in the 1970s (we should all want them to succeed). With 20 facilities across eight states and more on the way, Nutex is basically trying to be the Tesla of healthcare… minus the political volatility, plus actual cash flow. And in addition to operating hospitals, they’re managing them too (which gives them two revenue streams).

Now here’s what really made me spit out my oatmeal when doing research on the company: the suits at Benchmark recently raised its price target on Nutex Health from $60 to $150. That’s a 150% leap because Nutex went full beast mode in Q4, pulling in $94 million in adjusted EBITDA, flipping a $45.8 million loss in 2023 into a $52.2 million profit in 2024, and cranking out a 270% revenue increase to $257.6 million in just one quarter. Their yearly revenue nearly doubled to $479.9 million. 

And how’d they pull it off? Two words: arbitration hustle. The No Surprise Act (NSA), which originally crushed their out-of-network payments by 30%, turned out to be a blessing in disguise. Nutex stopped playing nice with insurers, embraced the HHS arbitration process, and started submitting 60-70% of claims for review. And they’re winning 80% of those cases. 

That strategy alone supercharged their EBITDA by 1,000% for the year. Benchmark thinks they’ll ride this momentum through 2025, and with the government finally smoothing out the arbitration process, Nutex now has a legal playbook to grow beyond this year. 

Oh and did I mention they’re expanding with three new hospitals set to open in late 2025, with more to follow in 2026? That’s a lot of growth stories to get excited about if you ask me.

Even with the stock up 280% year-to-date, it’s still rocking a surprisingly EBITDA of 5.64x and a P/E of 7.35x… both well below the healthcare peer group. Benchmark’s $150 target assumes a 6.3x multiple, which is still conservative. So yeah, it’ll be fun to see if this thing actually creeps toward that number. Keep an eye on it.

Stocks.News has positions in Nutex Health, Google, and Tesla.